Side-by-side · Research reference

HGH Fragment 176-191vsHumanin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED28/59 cited

BAnimal-StrongHUMAN-REVIEWED14/52 cited

HGH Fragment 176-191

GH Fragment · Pre-Clinical

50%Weight gain reductionNg 2000

~26 minHalf-life (est.)

No IGF-1 ↑GH axis impact

SQ · IP (animal) · Oral (tested)

Humanin

Mitochondrial-Derived Peptide · Cytoprotective

24-AAPeptide lengthZhu 2022

mtDNAEncoded originZhu 2022 Shahzaib 2026

Bax/BimPrimary targetZhu 2022 Morris 2021

SQ · Experimental

01Mechanism of Action

Parameter

HGH Fragment 176-191

Humanin

Primary target

Beta-3 adrenergic receptors on adipocytesHeffernan 2001

Intracellular: Bax, Bim, tBid (pro-apoptotic Bcl-2 family). Extracellular: FPRL1/2 G-protein-coupled receptorsZhu 2022 Lue 2021

Pathway

Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001

Humanin binds Bax/Bim → inhibits mitochondrial outer membrane permeabilization (MOMP) → blocks cytochrome c release → prevents caspase activation → cell survival

Downstream effect

Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation

Suppression of apoptosis, mitochondrial stabilization, reduced oxidative stress, preservation of germ cells and neurons under stressZhu 2022 Lue 2021 Velentza 2024

Feedback intact?

N/A — does not interact with GH/IGF-1 axis

Not applicable — peptide acts as anti-apoptotic signal, not hormonal axis

Origin

Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015

Encoded by short open reading frame in mitochondrial 16S rRNA gene (MTRNR2). 24-28 amino acids. 13 homologous variants (MTRNR2L1-L13) identified.Zhu 2022 Shahzaib 2026

Antibody development

Not reported in available studies

Not reported in animal models

02Dosage Protocols

Parameter

HGH Fragment 176-191

Humanin

Animal dose (oral)

500 mcg/kg body weightNg 2000

Obese Zucker rats, 19 days.

—

Animal dose (IP)

Not specified (14-day chronic administration)Heffernan 2001

Obese mice, daily IP injection.

—

Human equivalent dose

Not established — no published human RCTs

—

Frequency

Once daily (animal models)

Daily (IP)

Evidence basis

Animal studies only

Animal models (rat, mouse)Huang 2025 El 2022 Velentza 2024

Duration tested

14–19 daysHeffernan 2001 Ng 2000

—

Detection window

50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015

WADA-banned; anti-doping testing available.

—

Oral bioavailability

Demonstrated efficacy in animal oral administrationNg 2000

Potential for oral therapeutic development.

—

Standard experimental dose (HNG)

—

4 mg/kg IP (rat)

Most common dose in rodent models.

Ex vivo bone culture

—

1 µg/mL

Protective against venetoclax-induced bone growth retardation.

Duration

—

8–12 weeks in animal studies

Human data

—

None — no clinical trials reported

Analog (HNG)

—

Gly[14]-humanin — more potent variant

Substitution at position 14 enhances cytoprotective activity.

03Metabolic / Fat Loss Evidence

Parameter

HGH Fragment 176-191

Humanin

Primary fat target

Adipose tissue (general) — beta-3 AR mediated lipolysisHeffernan 2001

—

Weight gain reduction

50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000

Obese Zucker rats, 19 days oral administration.

—

Body fat reduction

Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001

—

Lipolytic activity

Increased adipose tissue lipolytic activityNg 2000

Direct measurement in treated animals.

—

Beta-3 AR expression

Upregulated β3-AR mRNA in obese mice to lean-comparable levelsHeffernan 2001

—

Insulin sensitivity

No adverse effect — euglycemic clamp confirmedNg 2000

Contrasts with intact hGH diabetogenic effects.

—

IGF-1 impact

No elevation — fragment does not activate GH/IGF-1 axis

—

Beta-3 AR dependency

Effect abolished in β3-AR knockout miceHeffernan 2001

Confirms β3-AR as primary mechanism.

—

Route of administration

Efficacy demonstrated via oral and IP routesNg 2000 Heffernan 2001

—

Human evidence

None published — pre-clinical only

—

Direct fat loss evidence

—

None

Mechanism overlap

—

Mitochondrial health may indirectly influence metabolic efficiency, but no quantified effect

04Side Effects & Safety

Parameter

HGH Fragment 176-191

Humanin

Insulin sensitivity

No adverse effects observed in euglycemic clamp (animal)Ng 2000

—

GH/IGF-1 axis

No activation — avoids diabetogenic effects of full GHNg 2000

—

Human safety data

Not available — no published human trials

None — no clinical trials

WADA status

Banned as performance-enhancing drugCox 2015

—

Metabolic profile

Six metabolites identified; CRSVEGSCG most stableCox 2015

Detection window implications for doping control.

—

Animal model safety

—

Well-tolerated in rat and mouse studies at 4 mg/kg for 8–12 weeks

Theoretical fibrillation risk

—

Induces amyloid-like fibrillation of Bax/BID. Long-term sequelae unknown.

Injection site reaction

—

Not reported in animal studies (IP route)

Reproductive safety

—

Protective in POI model (cyclophosphamide-induced), no adverse effects on fertility notedHuang 2025

Absolute Contraindications

HGH Fragment 176-191

·Competitive athletes (WADA-banned)Cox 2015

Humanin

·Unknown — no human data

Relative Contraindications

HGH Fragment 176-191

·Absence of human safety data — experimental use only

Humanin

·Active malignancy (theoretical risk of anti-apoptotic effect on tumour cells)

05Administration Protocol

Parameter

HGH Fragment 176-191

Humanin

1. Route

Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.

Intraperitoneal (IP) in animal models. Subcutaneous route untested. No human protocols exist.

2. Frequency

Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.

Synthetic peptide reconstituted in sterile saline or PBS. No commercial formulation available.

3. Duration

Animal protocols: 14–19 days. Human duration not established — no published trials.

Daily administration in animal studies. Optimal timing not characterized.

4. Storage

Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.

Lyophilised powder: -20 °C. Reconstituted: 4 °C, use within 7 days. Avoid freeze-thaw cycles.

5. Detection

Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015

No FDA approval, no IND, no clinical trials. Experimental research tool only.

06Stack Synergy

HGH Fragment 176-191

— no documented stacks

Humanin

+ MOTS-c

Multi-pathway

View MOTS-c →

Both are mitochondrial-derived peptides. MOTS-c enhances metabolic efficiency and insulin sensitivity via AMPK activation, while humanin prevents mitochondrial apoptosis. Combined, they address mitochondrial function (MOTS-c) and survival signaling (humanin), supporting cellular resilience under metabolic and oxidative stress.

Humanin: 4 mg/kg IP · daily (animal model)
MOTS-c: 5 mg/kg IP · daily (animal model)
Frequency: Once daily
Primary benefit: Mitochondrial health, metabolic efficiency, anti-apoptotic signaling